Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug delivery firm MicroDose Technologies has entered into a multi-product development and licensing agreement with Novartis for the MicroDose proprietary dry powder inhaler.
Subscribe to our email newsletter
This agreement follows the successful completion of an exploratory study performed with the MicroDose dry powder inhaler (DPI).
Under the terms of the agreement, including the initial payment, MicroDose could receive up to $125 million in milestones for the successful development of the first five products. In addition, Novartis will pay MicroDose development costs and royalties on product sales, and Novartis will fund the necessary development, manufacturing and marketing costs for all products.
In return, Novartis will receive exclusive rights to the MicroDose inhaler technology for its proprietary respiratory products.
“Novartis' strong pipeline of proprietary new chemical entities and in-licensed compounds, combined with MicroDose' next-generation inhaler, should ensure a strong leadership position in respiratory products for years to come,” noted Anand Gumaste, president and CEO of MicroDose.